Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

480 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies.
Thiébaut R, Jarne A, Routy JP, Sereti I, Fischl M, Ive P, Speck RF, D'Offizi G, Casari S, Commenges D, Foulkes S, Natarajan V, Croughs T, Delfraissy JF, Tambussi G, Levy Y, Lederman MM. Thiébaut R, et al. Among authors: routy jp. Clin Infect Dis. 2016 May 1;62(9):1178-1185. doi: 10.1093/cid/ciw065. Epub 2016 Feb 7. Clin Infect Dis. 2016. PMID: 26908786 Free PMC article. Clinical Trial.
Improvement of HIV-specific immunity in HIV-infected twins treated with highly active antiretroviral therapy, interleukin 2, and syngeneic adoptively transferred cells.
Tsoukas CM, Turner HM, Hatzakis GE, Blake GP, Goodhew JE, Kilby DL, Kovacs CM, Luetkehoelter JR, Routy JP, Walmsley SL, Bernard NF. Tsoukas CM, et al. Among authors: routy jp. AIDS Res Hum Retroviruses. 2001 Jul 1;17(10):887-900. doi: 10.1089/088922201750290014. AIDS Res Hum Retroviruses. 2001. PMID: 11461675 Clinical Trial.
Longitudinal assessment of changes in HIV-specific effector activity in HIV-infected patients starting highly active antiretroviral therapy in primary infection.
Alter G, Hatzakis G, Tsoukas CM, Pelley K, Rouleau D, LeBlanc R, Baril JG, Dion H, Lefebvre E, Thomas R, Côté P, Lapointe N, Routy JP, Sékaly RP, Conway B, Bernard NF. Alter G, et al. Among authors: routy jp. J Immunol. 2003 Jul 1;171(1):477-88. doi: 10.4049/jimmunol.171.1.477. J Immunol. 2003. PMID: 12817033
High rates of forward transmission events after acute/early HIV-1 infection.
Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, Baril JG, Thomas R, Rouleau D, Bruneau J, Leblanc R, Legault M, Tremblay C, Charest H, Wainberg MA; Quebec Primary HIV Infection Study Group. Brenner BG, et al. Among authors: routy jp. J Infect Dis. 2007 Apr 1;195(7):951-9. doi: 10.1086/512088. Epub 2007 Feb 16. J Infect Dis. 2007. PMID: 17330784
Interleukin-2 therapy in patients with HIV infection.
INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee; Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. INSIGHT-ESPRIT Study Group, et al. Among authors: routy jp. N Engl J Med. 2009 Oct 15;361(16):1548-59. doi: 10.1056/NEJMoa0903175. N Engl J Med. 2009. PMID: 19828532 Free PMC article. Clinical Trial.
Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.
Routy JP, Boulassel MR, Yassine-Diab B, Nicolette C, Healey D, Jain R, Landry C, Yegorov O, Tcherepanova I, Monesmith T, Finke L, Sékaly RP. Routy JP, et al. Clin Immunol. 2010 Feb;134(2):140-7. doi: 10.1016/j.clim.2009.09.009. Epub 2009 Nov 4. Clin Immunol. 2010. PMID: 19889582 Free PMC article. Clinical Trial.
480 results